Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cyteir Therapeutics Inc (CYT)

Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,714
  • Shares Outstanding, K 35,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,060 K
  • 60-Month Beta 0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.87
Trade CYT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings $-0.10 on 11/06/23
  • Latest Earnings Date 03/28/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.99 +1.00%
on 03/08/24
3.15 -4.13%
on 03/11/24
-0.09 (-2.89%)
since 02/15/24
3-Month
2.99 +1.00%
on 03/08/24
3.19 -5.33%
on 02/09/24
-0.07 (-2.27%)
since 12/15/23
52-Week
1.48 +104.05%
on 03/16/23
3.19 -5.33%
on 02/09/24
+1.52 (+101.33%)
since 03/15/23

Most Recent Stories

More News
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851

Cyteir Announces Halt of CYT-0851 Development and Company Dissolution Biotech firm Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced today its decision

CYT : 3.02 (-2.27%)
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?

Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.

IMGN : 31.23 (unch)
CYT : 3.02 (-2.27%)
CPRX : 15.10 (-0.20%)
ACRV : 9.51 (+1.28%)
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results...

CYT : 3.02 (-2.27%)
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President...

CYT : 3.02 (-2.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cyteir Therapeutics Inc. is a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer. Cyteir Therapeutics Inc. is based in LEXINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 3.16
2nd Resistance Point 3.13
1st Resistance Point 3.07
Last Price 3.02
1st Support Level 2.98
2nd Support Level 2.95
3rd Support Level 2.89

See More

52-Week High 3.19
Last Price 3.02
Fibonacci 61.8% 2.54
Fibonacci 50% 2.34
Fibonacci 38.2% 2.13
52-Week Low 1.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar